The Role of Glypican-1 in the Tumour Microenvironment.

Angiogenesis GPC-1 Glypican-1 Growth factor signalling Invasion Metastasis Pancreatic cancer Stroma Therapeutics Tumour microenvironment

Journal

Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103

Informations de publication

Date de publication:
2020
Historique:
entrez: 9 4 2020
pubmed: 9 4 2020
medline: 18 4 2020
Statut: ppublish

Résumé

Glypican-1 (GPC-1) is a cell surface heparan sulphate proteoglycan that is critical during normal development, but which is not required for normal homoeostasis in the adult. It is, however, overexpressed in a variety of solid tumours and is known to regulate tumour growth, invasion, metastasis and progression, through modulation of tumour cell biology as well as influence on the tumour microenvironment (TME). The role of GPC-1 in the TME and on the tumour cell is broad, as GPC-1 regulates signalling by several growth factors, including FGF, HGF, TGF-β, Wnt and Hedgehog (Hh). Signalling via these pathways promotes tumour growth and invasive and metastatic ability (drives epithelial-to-mesenchymal transition (EMT)) and influences angiogenesis, affecting both tumour and stromal cells. Broad modulation of the TME via inhibition of GPC-1 may represent a novel therapeutic strategy for inhibition of tumour progression. Here, we discuss the complex role of GPC-1 in tumour cells and the TME, with discussion of potential therapeutic targeting strategies.

Identifiants

pubmed: 32266658
doi: 10.1007/978-3-030-40146-7_8
doi:

Substances chimiques

Glypicans 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

163-176

Auteurs

Maria E Lund (ME)

GlyTherix Ltd, Sydney, NSW, Australia. Maria.lund@glytherix.com.

Douglas H Campbell (DH)

GlyTherix Ltd, Sydney, NSW, Australia.

Bradley J Walsh (BJ)

GlyTherix Ltd, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH